Gestational Hypertension (GH) is a common complication during pregnancy, which not only poses a threat to the life and health of the pregnant woman but also has a great impact on the healthy development of the fetus. Early diagnosis, close prenatal monitoring, and timely intervention are the keys to dealing with GH. However, economical, reproducible, and reliable GH biomarkers are urgently needed to be discovered. At present, there are more and more studies on the potential markers and possible mechanisms in the exosomes of GH patients. These discovered biomarkers in exosomes may be involved in the occurrence and development of GH, which can provide assistance for early diagnosis and treatment. Creative Biolabs has been committed to developing the potential of exosomes in the diagnosis of GH and can provide customers with the most comprehensive high-throughput sequencing technology.

The Potential Value of Exosomes in the Diagnosis of Gestational Hypertension

GH refers to a group of diseases that coexist with pregnancy and elevated blood pressure. Among this group of diseases, preeclampsia (PE) and eclampsia, which seriously affect the health of mother and child, are the leading causes of maternal and perinatal mortality. The clinical manifestations of GH include elevated blood pressure, proteinuria, edema, and damage to multiple organs throughout the body. Convulsions (eclampsia), coma, etc. may occur in patients with severe GH. Several studies have shown that exosome concentrations are significantly increased in the blood of pregnant women with GH compared with normal pregnancies, which correlates with the severity of the disease. High-throughput sequencing technology is an experimental method developed in recent years that can perform high-throughput and panoramic research on gene expression in diseases. Through high-throughput sequencing technology, a large number of studies have found that exosomes derived from the blood, placenta, and amniotic fluid of GH patients contain a variety of differentially expressed bioactive molecules (including proteins, lipids, nucleic acids, etc.). Therefore, studying the changes of exosome contents in pregnant women can provide a research basis and reference for the early diagnosis of GH.

Fig.1 Unique microRNA signals in plasma exosomes from pregnancies complicated by preeclampsia. (Li, 2020)

Creative Biolabs Sequencing Service Advantages

☺ Has rich experience in exosomal RNA and protein extraction. In addition, we can provide extraction solutions for easily degradable samples and trace samples.

☺ Professional experimenters are equipped from sample processing to machine testing. They have rich experience in experimental operations, follow strict quality control standards, and check at every level to ensure high-quality completion of experiments.

☺ Equipped with an experienced analysis team. In addition to being able to quickly complete basic analysis, they can also complete personalized analysis according to customer needs and provide various advanced charts.

☺ The most powerful one-stop exosomal sequencing platform has been established. This platform includes exosomal proteome sequencing, exosomal whole transcriptome sequencing, exosomal miRNA sequencing, exosomal lncRNA sequencing, exosomal circRNA sequencing, etc.

Creative Biolabs is a world-leading provider of exosome research services. You can discover the most valuable biomarkers in the exosomes of pregnant women to diagnose GH on our exosomal sequencing platform. Please feel free to contact us with your experimental needs, and our scientific consultants will reply to you as soon as possible.

Reference

1. Li, H.; Ouyang, Y.; et al. Unique microRNA signals in plasma exosomes from pregnancies complicated by preeclampsia. Hypertension. 2020. 75(3):762-771.

• Prenatal Screening-Applied Exosomes
• Gestational Diabetes Mellitus Diagnosis-Applied Exosome